Your browser doesn't support javascript.
loading
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai, Shogo; Togashi, Yosuke; Kamada, Takahiro; Sugiyama, Eri; Nishinakamura, Hitomi; Takeuchi, Yoshiko; Vitaly, Kochin; Itahashi, Kota; Maeda, Yuka; Matsui, Shigeyuki; Shibahara, Takuma; Yamashita, Yasuho; Irie, Takuma; Tsuge, Ayaka; Fukuoka, Shota; Kawazoe, Akihito; Udagawa, Hibiki; Kirita, Keisuke; Aokage, Keiju; Ishii, Genichiro; Kuwata, Takeshi; Nakama, Kenta; Kawazu, Masahito; Ueno, Toshihide; Yamazaki, Naoya; Goto, Koichi; Tsuboi, Masahiro; Mano, Hiroyuki; Doi, Toshihiko; Shitara, Kohei; Nishikawa, Hiroyoshi.
Affiliation
  • Kumagai S; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Togashi Y; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kamada T; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Sugiyama E; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Nishinakamura H; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Takeuchi Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Vitaly K; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Itahashi K; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Maeda Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Matsui S; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Shibahara T; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Yamashita Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Irie T; Department of Biostatics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Tsuge A; Research and Development Group, Hitachi Ltd., Tokyo, Japan.
  • Fukuoka S; Research and Development Group, Hitachi Ltd., Tokyo, Japan.
  • Kawazoe A; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Udagawa H; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Kirita K; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Aokage K; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Ishii G; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Kuwata T; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Nakama K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Kawazu M; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.
  • Ueno T; Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan.
  • Yamazaki N; Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan.
  • Goto K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Tsuboi M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Doi T; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Shitara K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Nishikawa H; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.
Nat Immunol ; 21(11): 1346-1358, 2020 11.
Article in En | MEDLINE | ID: mdl-32868929
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Regulation / T-Lymphocytes, Regulatory / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Nat Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2020 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Regulation / T-Lymphocytes, Regulatory / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Nat Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2020 Type: Article Affiliation country: Japan